Table 2.
Definition of poor risk localised disease and indications for busulfan and melphalan (BuMel) high-dose therapy
| Case | Localised disease | Resected at diagnosis | Volume ≥200 mL | Pre-operative RT | Histological response ≥10% viable tumour |
Unresectable tumour treated with RT alone | Volume <200 mL but poor radiological response i.e., <50% regression with chemotherapy | RT contraindications to BuMela | Other medical contraindications to BuMela | BuMel recommended |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | N | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r | N |
| 2 | Y | Y | N | n/r | n/r | n/r | n/r | n/r | n/r | N |
| 3 | Y | Y | Y | n/r | n/r | n/r | n/r | N | N | Y |
| 4 | Y | N | N | n/r | Y | n/r | n/r | N | N | Y |
| 5 | Y | N | N | Y | Y | n/r | n/r | N | N | Y |
| 6 | Y | N | Y | N | Y | n/r | n/r | N | N | Y |
| 7 | Y | N | Y | Y | Y | n/r | n/r | N | N | Y |
| 8 | Y | N | Y | Y | N | n/r | n/r | N | N | Y |
| 9 | Y | N | Y | Y | n/ab | n/r | n/r | N | N | Y |
| 10 | Y | N | Y | N | n/a | Y | n/r | N | N | Y |
| 11 | Y | N | N | N | n/a | Y | Y | N | N | Y |
n/a not available, n/r not relevant, RT radiotherapy
aIf response is yes, then high-dose therapy is contraindicated
bFor example, if extracorporeal irradiation of primary tumour is used prior to re-implantation